Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 1 August 2024 AM
The PBAC has dropped a mammoth agenda for its upcoming meeting in November, lining up a total of 61 submissions for consideration.
New PBS listing submissions dominate the list at 37, followed by 18 change to existing listing submissions, two new NIP listing submissions and one 'other matters' submission. It will also consider three sub-committee DUSC analysis reports submitted by Novartis, Gilead, and MSD.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.